Fennec Pharmaceuticals Inc. Posts $19.6 Million Revenue, $0.12 Diluted GAAP EPS

Fennec Pharmaceuticals Inc. posted $19.608 million in total revenue and $0.12 in diluted GAAP EPS for the third quarter of 2026, providing two key measures of its quarterly results.

Revenue included $19.425 million in net product sales and $183,000 in other revenue. Together, those amounts brought total revenue to $19.608 million, or $19.6 million when rounded.

Basic GAAP earnings per share was $0.13. Earnings per share expresses a company’s earnings on a per-share basis, while generally accepted accounting principles (GAAP) are accounting rules used to prepare financial statements.